BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 50.2% during the second quarter, HoldingsChannel.com reports. The firm owned 51,024 shares of the biotechnology company’s stock after selling 51,469 shares during the quarter. Seven Fleet Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $510,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the period. Allworth Financial LP purchased a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $52,000. Focus Partners Wealth purchased a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Elevation Point Wealth Partners LLC acquired a new position in BioCryst Pharmaceuticals during the third quarter valued at approximately $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $9.96 on Friday. The company has a market capitalization of $2.55 billion, a P/E ratio of -6.64 and a beta of 0.57. The company has a 50-day moving average of $9.75 and a 200-day moving average of $9.17. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.15 earnings per share. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada cut their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald increased their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Wedbush cut their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.